Summary • Erasca, Inc. (ERAS) shares rose 14.1% to $3.30 amid conference participation.• The company is attending the Evercore Healthcare Conference to discuss RAS/MAPK therapy advancements.• Analysts ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...

On November 14, 2025, Erasca, Inc. (NASDAQ:ERAS) saw Guggenheim’s analyst Michael Schmidt reiterate a “Buy” rating with a $5 ...

The human body experiences various health problems because of inflammation, which can lead to joint pain, heart disease and ...

In this piece, we will discuss the 12 hot penny stocks to invest in right now. Amid an uncertain macro environment, where the economic outlook is blurry, the momentum of penny stocks depends heavily ...

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

Pasithea Therapeutics Corp (NASDAQ: KTTA) shares are trading sharply higher Wednesday following a string of upbeat updates.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

Presentation time: December 4, 11:10-11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor). The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research ---- The Hoffman ALS Clinical Trial Awards ...

Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) ...